REVOLUTION MEDICINES INC (RVMD) Forecast, Price Target & Analyst Ratings

Q: What is the average price target for REVOLUTION MEDICINES INC (RVMD) stock?

27 analysts have analysed RVMD and the average price target is 136.84 USD. This implies a price decrease of -8.23% is expected in the next year compared to the current price of 149.115.

Q: What is the next earnings date for RVMD stock?

REVOLUTION MEDICINES INC (RVMD) will report earnings on 2026-05-11, after the market close.

NASDAQ:RVMD • US76155X1000

149.115 USD

+0.49 (+0.33%)

Last: Apr 20, 2026, 03:03 PM

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for REVOLUTION MEDICINES INC (RVMD).

Consensus Price Target

Price Target

$136.84

-8.23% Downside

→ Price target details

Next Earnings Forecast

Earnings Estimate

Release Date: May 11, 2026
Period: Q1 / 2026
EPS Estimate: -$1.87
Revenue Estimate: 3.645M

→ Full earnings forecast details

ChartMill Buy Consensus

Rating

87.41%

Weighted Analyst Rating Score

→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target

$136.84

Upside

-8.23%

From current price of $149.12 to mean target of $136.84, Based on 27 analyst forecasts

Low

$73.73

Median

$142.80

High

$178.50

Price Target Revisions

1 Month

10.02%

3 Months

47.43%

Price Target Summary

27 Wall Street analysts provided a forecast for the next 12 months for RVMD. The average price target is 136.84 USD. This implies a price decrease of -8.23% is expected in the next year compared to the current price of 149.115.

The average price target has been revised upward by 47.43% in the past 3 months.

→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

Analyst Ratings History

Analyst Ratings Consensus

ChartMill Buy Consensus

87.41%

RVMD was analyzed by 27 analysts. The buy percentage consensus is at 87. So analysts seem to be very confident about RVMD.

In the previous month the buy percentage consensus was at a similar level.

RVMD was analyzed by 27 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.

→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

Date	Firm	Action	From → To
2026-04-20	Needham	Maintains	Buy -> Buy
2026-04-20	Stifel	Reiterate	Buy -> Buy
2026-04-14	Guggenheim	Maintains	Buy -> Buy
2026-04-14	RBC Capital	Maintains	Outperform -> Outperform
2026-04-14	Wedbush	Reiterate	Outperform -> Outperform
2026-04-14	Wells Fargo	Maintains	Overweight -> Overweight
2026-04-14	Evercore ISI Group	Maintains	Outperform -> Outperform
2026-04-14	HC Wainwright & Co.	Maintains	Buy -> Buy
2026-04-13	Leerink Partners	Maintains	Outperform -> Outperform
2026-04-13	Oppenheimer	Maintains	Outperform -> Outperform
2026-02-26	Needham	Maintains	Buy -> Buy
2026-02-26	Wells Fargo	Maintains	Overweight -> Overweight
2026-02-26	Piper Sandler	Maintains	Overweight -> Overweight
2026-02-02	JP Morgan	Maintains	Overweight -> Overweight
2026-01-27	Oppenheimer	Maintains	Outperform -> Outperform
2026-01-22	Stifel	Maintains	Buy -> Buy
2026-01-21	RBC Capital	Maintains	Outperform -> Outperform
2026-01-20	Guggenheim	Maintains	Buy -> Buy
2026-01-13	Mizuho	Maintains	Outperform -> Outperform
2025-11-18	Wolfe Research	Initiate	Outperform
2025-11-06	Needham	Maintains	Buy -> Buy
2025-11-06	Wedbush	Maintains	Outperform -> Outperform
2025-11-06	JP Morgan	Maintains	Overweight -> Overweight
2025-11-06	HC Wainwright & Co.	Maintains	Buy -> Buy
2025-11-03	RBC Capital	Initiate	Outperform

Next Earnings Forecast Details

Next Earnings Details

Release Date: May 11, 2026
Period: Q1 / 2026
EPS Estimate: -$1.87
Revenue Estimate: 3.645M
Revenue Q2Q: N/A
EPS Q2Q: -65.42%
Number of Analysts: 20

Next Earnings Revisions

Revenue (1 Month)

-6.66%

Revenue (3 Months)

N/A

EPS (1 Month)

-0.53%

EPS (3 Months)

-10.53%

Next Earnings Summary

RVMD is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -1.87 USD and the consensus revenue estimate is 3.65M USD.

→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

	2021	2022	2023	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033
Revenue YoY % growth	29.39M -31.62%	35.38M 20.38%	11.58M -67.27%	306K -100.00%	4.502M	54.869M	347.33M 533.02%	926.75M 166.82%	2.18B 135.23%	3.759B 72.43%	5.318B 41.47%	6.531B 22.81%	8.033B 23.00%
EBITDA YoY % growth	-183.86M -71.80%	-253.24M -37.74%	-481.075M -89.97%	-673.512M -41.74%	-1.153B -72.13%	-1.625B -38.45%	-1.477B 9.10%	-1.072B 27.46%	-368.832M 65.58%	1.021B 376.82%	2.675B 162.00%	4.222B 57.83%	5.826B 37.99%
EBIT YoY % growth	-188.01M -69.84%	-258.28M -37.38%	-487.185M -88.63%	-680.641M -41.53%	-1.158B -71.48%	-1.573B -33.04%	-1.364B 13.28%	-1.009B 26.06%	1.179M 100.12%	1.297B 109,908.48%	2.433B 87.59%	3.601B 48.01%	4.668B 29.63%
Operating Margin	-639.71%	-730.02%	-4,207.12%	-222,431.83%	-25,730.04%	-2,866.80%	-392.72%	-108.83%	0.05%	34.50%	45.75%	55.14%	58.11%
EPS YoY % growth	-2.56 -19.63%	-3.10 -21.09%	-3.77 -21.71%	-3.54 5.38%	-5.70 -65.55%	-7.88 -33.36%	-6.83 13.31%	-4.95 27.53%	-0.11 97.80%	6.17 5,765.98%	9.98 61.85%	15.12 51.51%	20.16 33.29%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

	Q1 / 26	Q2 / 26	Q3 / 26	Q4 / 26	Q1 / 27	Q2 / 27	Q3 / 27	Q4 / 27	Q1 / 28	Q2 / 28	Q3 / 28	Q4 / 28
EPS Q2Q % growth	-1.87 -65.42%	-1.89 -44.11%	-2.07 -28.87%	-2.06 -10.49%	-1.94 -3.79%	-1.91 -1.36%	-1.84 11.41%	-1.84 10.46%	-1.67 13.77%	-1.57 17.91%	-1.62 11.76%	-1.57 14.63%
Revenue Q2Q % growth	3.645M	20.645M	3.645M	28.153M	39.78M 991.36%	53.499M 159.14%	70.312M 1,829.00%	123.04M 337.04%	112.2M 182.05%	117.3M 119.26%	132.6M 88.59%	151.78M 23.36%
EBITDA Q2Q % growth	-384.099M -65.36%	-404.556M -55.16%	-425.45M -37.71%	-420.087M -19.01%	-396.78M -3.30%	-409.02M -1.10%	-425.34M 0.03%	-415.14M 1.18%	-349.33M 11.96%	-352.777M 13.75%	-351.135M 17.45%	-338.15M 18.55%
EBIT Q2Q % growth	-382.566M -73.65%	-400.737M -51.38%	-422.745M -34.09%	-418.276M -15.67%	-389.691M -1.86%	-379.8M 5.22%	-362.773M 14.19%	-453.385M -8.39%	-350.39M 10.09%	-353.879M 6.82%	-349.483M 3.66%	-342.516M 24.45%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year

5.14%

EPS Next 5 Year

24.93%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year

490.45%

Revenue Next 5 Year

284.00%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year

2.44%

EBIT Next 5 Year

23.57%

→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

REVOLUTION MEDICINES INC / RVMD Forecast FAQ

What is the average price target for REVOLUTION MEDICINES INC (RVMD) stock?

27 analysts have analysed RVMD and the average price target is 136.84 USD. This implies a price decrease of -8.23% is expected in the next year compared to the current price of 149.115.

What is the next earnings date for RVMD stock?

REVOLUTION MEDICINES INC (RVMD) will report earnings on 2026-05-11, after the market close.

Can you provide the consensus estimates for REVOLUTION MEDICINES INC next earnings?

The consensus EPS estimate for the next earnings of REVOLUTION MEDICINES INC (RVMD) is -1.87 USD and the consensus revenue estimate is 3.65M USD.

What is the expected long term growth rate for REVOLUTION MEDICINES INC (RVMD)?

The expected long term growth rate for REVOLUTION MEDICINES INC (RVMD) is 490.45%.

Analyst forecast overview

Forecast Snapshot